Sodium glycerophosphate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{DrugProjectFormSinglePage |authorTag= <!--Overview--> |genericName= |aOrAn= a |drugClass= |indication= |hasBlackBoxWarning= Yes |adverseReactions= <!--Bla...")
 
No edit summary
Line 23: Line 23:
|hasBlackBoxWarning=
|hasBlackBoxWarning=


Yes


|adverseReactions=
|adverseReactions=
Line 93: Line 92:


|offLabelPedNoGuideSupport=
|offLabelPedNoGuideSupport=


There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
Line 102: Line 99:
|contraindications=
|contraindications=


* Condition1
*Glycophos should not be given to patients in a state of dehydration or with [[hypernatraemia]], [[hyperphosphataemia]], severe [[renal insufficiency]] or [[shock]].


<!--Warnings-->
<!--Warnings-->
Line 117: Line 114:


There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.




Line 125: Line 121:


There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.




Line 132: Line 127:
|drugInteractions=
|drugInteractions=


* Drug
*No interactions with other drugs have been observed, but a moderate fall in serum phosphate can be seen during carbohydrate infusions.
:* Description
 
<!--Use in Specific Populations-->
<!--Use in Specific Populations-->


Line 140: Line 133:
*Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when Glycophos is administered during pregnancy.
*Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when Glycophos is administered during pregnancy.
|useInPregnancyAUS=
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
Line 164: Line 156:


|useInRenalImpair=
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
There is no FDA guidance on the use of {{PAGENAME}} in patients with [[renal impairment]].


|useInHepaticImpair=
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
There is no FDA guidance on the use of {{PAGENAME}} in patients with [[hepatic impairment.]]


|useInReproPotential=
|useInReproPotential=
Line 173: Line 165:


|useInImmunocomp=
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
There is no FDA guidance one the use of {{PAGENAME}} in patients who are [[immunocompromised]].


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->


|administration=
|administration=
* Oral


* Intravenous
* Intravenous
Line 186: Line 176:


There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 212: Line 200:


|mechAction=
|mechAction=
*


<!--Structure-->
<!--Structure-->
Line 219: Line 205:
|structure=
|structure=


*  
* The active ingredient in 1 ml of Glycophos correspond to
:*Phosphate        1 mmol
:*Sodium            2 mmol


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
Line 249: Line 236:
<!--How Supplied-->
<!--How Supplied-->


|howSupplied=
|howSupplied=*Glycophos may only be added to or mixed with other medicinal products for which compatibility has been documented. See 5.6.
 
*Shelf life is 3 years
 
*Special precautions for storage
 
:*Do not store above 25°C. Do not freeze.
 
:*Nature and contents of container
 
:8Polypropylene vial.
 
:*Pack size: 10 x 20 ml
 
*Instructions for use/handling
 
:*Glycophos must not be given undiluted.


*


<!--Patient Counseling Information-->
<!--Patient Counseling Information-->
Line 269: Line 271:
|brandNames=
|brandNames=


* ®<ref>{{Cite web | title =  | url =  }}</ref>
*GLYCOPHOS


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
Line 275: Line 277:
|lookAlike=
|lookAlike=


* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 


<!--Drug Shortage Status-->
<!--Drug Shortage Status-->

Revision as of 20:08, 24 April 2015

Sodium glycerophosphate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Sodium glycerophosphate is a that is FDA approved for the {{{indicationType}}} of . Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

Posology and method of administration

  • Glycophos must not be given undiluted.
Adults:
  • The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 ml of Glycophos added to the infusion solution or to the admixture for which compatibility has been proved.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sodium glycerophosphate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sodium glycerophosphate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

Posology and method of administration

  • Glycophos must not be given undiluted.
Infants:
  • The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/Kg body weight/day.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sodium glycerophosphate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sodium glycerophosphate in pediatric patients.

Contraindications

Warnings

  • Glycophos should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly.

Glycophos must not be given undiluted.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Sodium glycerophosphate in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Sodium glycerophosphate in the drug label.

Drug Interactions

  • No interactions with other drugs have been observed, but a moderate fall in serum phosphate can be seen during carbohydrate infusions.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when Glycophos is administered during pregnancy.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sodium glycerophosphate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sodium glycerophosphate during labor and delivery.

Nursing Mothers

  • Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.
  • No adverse events are to be expected when Glycophos is administered during pregnancy.

Pediatric Use

There is no FDA guidance on the use of Sodium glycerophosphate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Sodium glycerophosphate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Sodium glycerophosphate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sodium glycerophosphate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sodium glycerophosphate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sodium glycerophosphate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sodium glycerophosphate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sodium glycerophosphate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Intravenous

Monitoring

There is limited information regarding Monitoring of Sodium glycerophosphate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Sodium glycerophosphate in the drug label.

Overdosage

  • No adverse effects of an overdose have been reported. Most patients in need of intravenous nutrition have an increased capacity to handle glycerophosphate.

Pharmacology

There is limited information regarding Sodium glycerophosphate Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Sodium glycerophosphate Mechanism of Action in the drug label.

Structure

  • The active ingredient in 1 ml of Glycophos correspond to
  • Phosphate 1 mmol
  • Sodium 2 mmol

Pharmacodynamics

  • Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.

Pharmacokinetics

  • To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.
  • No pharmacokinetical data is available for infants, however with the recommended dosage hyperphosphataemia is unlikely.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Sodium glycerophosphate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Sodium glycerophosphate in the drug label.

How Supplied

  • Glycophos may only be added to or mixed with other medicinal products for which compatibility has been documented. See 5.6.
  • Shelf life is 3 years
  • Special precautions for storage
  • Do not store above 25°C. Do not freeze.
  • Nature and contents of container
8Polypropylene vial.
  • Pack size: 10 x 20 ml
  • Instructions for use/handling
  • Glycophos must not be given undiluted.

Storage

There is limited information regarding Sodium glycerophosphate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sodium glycerophosphate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sodium glycerophosphate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Sodium glycerophosphate in the drug label.

Precautions with Alcohol

  • Alcohol-Sodium glycerophosphate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • GLYCOPHOS

Look-Alike Drug Names

There is limited information regarding Sodium glycerophosphate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.



{{#subobject: 

 |Label Page=Sodium glycerophosphate
 |Label Name=Sodium glycerophosphate02.png

}}


{{#subobject: 

 |Label Page=Sodium glycerophosphate
 |Label Name=Sodium glycerophosphate03.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Sodium_glycerophosphate&oldid=1091683"